Computational toxicology and in silico predictionprimary
2 projects
Both EU-ToxRisk and eTRANSAFE rely on Lhasa's predictive models, read-across methods, and cheminformatics for non-animal toxicity assessment.
Organization
LHASA LIMITED
UK-based not-for-profit specialising in computational toxicology, cheminformatics and predictive safety models used widely by pharma and chemical regulators.
Research institutehealthUKNo active H2020 projects
H2020 projects
2
As coordinator
0
Total EC funding
€3.2M
Unique partners
65
What they do
Their core work
Lhasa Limited develops computational tools and curated knowledge bases for predicting the toxicity and safety of chemicals and drugs without animal testing. Their work combines cheminformatics, adverse outcome pathway modelling, read-across methods and integration of pre-clinical safety data (including SEND-format pharma data). They are best known in the pharmaceutical and chemical industries for in silico prediction systems that regulators and R&D teams use to flag genotoxicity, organ toxicity and metabolic risk. In EU projects they act as the specialist who turns mechanistic biology and experimental data into usable predictive models.
Core expertise
What they specialise in
Adverse Outcome Pathway (AOP) modellingprimary
1 project
EU-ToxRisk explicitly uses AOPs and mechanism-based toxicity testing as its scientific backbone.
Pharmaceutical safety data integration (SEND, pre-clinical)primary
1 project
eTRANSAFE (EUR 2.93M participation) focuses on integrating pre-clinical SEND-format data to improve translational safety assessment.
Cheminformatics and structure-activity knowledge basessecondary
2 projects
Keywords across both projects cite cheminformatics, read-across, and predictive models — Lhasa's core commercial capability (Derek, Sarah, Vitic).
Data sharing and interoperability for regulatory scienceemerging
1 project
eTRANSAFE emphasises data sharing, integration and interoperability across pharma companies and regulators.
Evolution & trajectory
How they've shifted over time
Early focus
Mechanism-based toxicity testing
Recent focus
Drug safety data integration
Lhasa entered H2020 in 2016 through EU-ToxRisk, contributing mechanism-based toxicity testing, AOPs, biokinetics and computational modelling for chemical risk assessment. By 2017 their focus had shifted decisively toward pharmaceutical safety with eTRANSAFE, which is eight times larger in EC funding and emphasises drug safety, SEND pre-clinical data, and cross-industry data interoperability. The trajectory moves clearly from chemical/regulatory toxicology toward drug development informatics and shared safety databases.
They are moving from chemical regulatory toxicology toward pharmaceutical drug-safety data infrastructure — a strong fit for consortia combining pre-clinical data, AI/ML, and industry data-sharing frameworks.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European14 countries collaborated
Lhasa consistently joins large, ambitious consortia as a specialist partner rather than coordinating. With 65 unique partners across just 2 projects, they operate in very wide networks — both EU-ToxRisk and eTRANSAFE are flagship-scale initiatives bringing together academia, regulators, and pharma. They contribute a specific technical capability (predictive toxicology, data integration) rather than general research capacity, which makes them a reliable "plug-in" expert partner.
Very broad network for just two projects: 65 unique partners across 14 countries, reflecting participation in flagship toxicology and pharma consortia that span most EU research-intensive countries. Headquartered in Leeds, UK, but operating across European academia, regulatory bodies, and pharmaceutical industry.
Why partner with them
What sets them apart
Lhasa is a rare example of a not-for-profit research organisation that also operates industry-grade predictive toxicology software (used by most major pharmaceutical companies and regulators). This gives them an unusual dual identity: academic enough to join research consortia, commercial enough to maintain production-quality cheminformatics platforms. For a partner, this means you get deployable tools and curated knowledge bases, not just research prototypes.
Notable projects
Highlights from their portfolio
- eTRANSAFEBy far their largest H2020 engagement (EUR 2.93M), a long-running IMI-style initiative pooling pre-clinical safety data across pharma companies to improve drug safety prediction.
- EU-ToxRiskA European flagship programme on non-animal, mechanism-based chemical risk assessment — Lhasa's AOP and cheminformatics tools sit at the heart of its methodology.
Cross-sector capabilities
Chemicals and REACH regulationPharmaceuticals and drug developmentFood safety and ingredient assessmentCosmetics safety testing
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →